title: [LMB chemotherapy for mature B-cell neoplasms in children: a single-center experience].
abstract: BACKGROUND
  LMB chemotherapy based on the FAB LMB96 study is internationally accepted as one of the standard treatments for pediatric B-cell non-Hodgkin lymphoma (B-NHL), though experience with this regimen in Japan is very limited. Since 2009, we have administered LMB chemotherapy to children with B-NHL at the National Center for Child Health and Development. Thus, we herein report the clinical characteristics and outcomes of 13 children with B-NHL given LMB chemotherapy.
  
  
  RESULTS
  Median age was 7.5 years. Five patients were girls and 8 were boys. Nine were subclassified as having Burkitt lymphoma and 4 as having diffuse large B-cell lymphoma. According to the St. Jude staging system, 3, 4, 2, 1, and 3 patients had stages 1, 2, 3, 4, and B-ALL disease, respectively. According to the LMB group classification system, nine patients were classified into Group B and four into Group C. At a median follow-up of 2.3 years, all patients are alive without lymphoma relapse. In Group C, myelosuppression and severe mucositis were the main adverse events especially during induction therapy. High-dose methotrexate at a dose of 8 g/m2 was manageable using standard supportive therapy even with 24-hour infusion.
  
  
  CONCLUSIONS
  Our experience indicates the feasibility of LMB chemotherapy for Japanese children with B-NHL.
authors.affiliation: Children's Cancer Center, National Center for Child Health and Development.
authors.forename: Tomoo
authors.initials: T
authors.lastname: Osumi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Mori
authors.forename: Yoko
authors.initials: Y
authors.lastname: Shioda
authors.forename: Chikako
authors.initials: C
authors.lastname: Kiyotani
authors.forename: Keita
authors.initials: K
authors.lastname: Terashima
authors.forename: Motohiro
authors.initials: M
authors.lastname: Kato
authors.forename: Daisuke
authors.initials: D
authors.lastname: Tomizawa
authors.forename: Kentaro
authors.initials: K
authors.lastname: Ohki
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Kiyokawa
authors.forename: Hideto
authors.initials: H
authors.lastname: Iwafuchi
authors.forename: Takako
authors.initials: T
authors.lastname: Yoshioka
authors.forename: Atsuko
authors.initials: A
authors.lastname: Nakazawa
authors.forename: Kimikazu
authors.initials: K
authors.lastname: Matsumoto
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction; D012189:Retrospective Studies